• First commercialization success for Curiox
• Further aggressive expansion planned in Asia
• Long-term sights set on EU and USA

Singapore, 26 May 2008

Curiox Biosystems Pte Ltd of Singapore has entered into a sales partnership agreement with Seoul-based BioBud Inc. covering the exclusive distribution of the Curiox DropArray™ Products in the Republic of Korea. The patented technology platform from Curiox facilitates the convenient and cost-efficient miniaturization of aqueous bioassays for drug discovery and other life science applications. The technology from Curiox enables up to a thousand-fold reduction in the amount of material and reagent required while simultaneously reducing reaction time up to by a factor of ten.

Sales are expected to reach a few million U.S. dollars over the next three years with potentially much larger revenues from new products currently in the development pipeline. Korea is one of most active countries in Asia in the biotech sector. According to the Bioindustry Association of Korea, the size of its biotech market was USD 2.7 billion in 2006, with an annual growth rate of approx. 18%. Curiox's DropArray™ product line is expected to take advantage of this rapidly growing market. Curiox's products will help Korean customers compete more effectively in this increasingly competitive market by reducing operating costs and time significantly, while enabling challenging research projects with limited samples and reagents.

Namyong Kim, CEO of Curiox, commented on the new agreement, "BioBud is the first international distributor for Curiox. The distribution partnership represents an excellent opportunity for both companies, Curiox and BioBud. The distribution contract with a leading Korean biotech company, BioBud, shows the level of trust in, and superiority of, DropArray™ products in spite of our company's short history. BioBud's extensive network and understanding of the Korean biotech market is expected to provide the ideal partnership for Curiox to enter and capture this market."

Jae Hoon Hwang, CEO of BioBud, added, "I am extremely pleased about the partnership with Curiox. Its DropArray™ products will upgrade BioBud's status in the Korean biotech market while increasing its revenue from distribution. On the technical level, it is my pleasure to introduce such innovative products to the Korean market earlier than any other major countries and to offer this great opportunity to Korean researchers. I am confident that BioBud's significant customer database and experience in research will speed up market acceptance of DropArray™ products."

Singapore and Korea are the first markets in which Curiox's DropArray™ product line is being launched. These markets provide a sufficient base of potential customers to provide reasonable revenues along with valuable feedback on the products. As a next step, Curiox intends to expand the distribution of its products to other countries in the Asia Pacific region such as Japan, Hong Kong, Taiwan and Australia. This will be followed by Germany, the remainder of the European Union, and the USA.

BioBud, founded in 2000 by renowned professors from top Korean medical schools, is one of the leading private biotech companies in Korea. It has successfully raised a significant amount of investment and received a number of top government research grants which have enabled proprietary technical innovations. Most notably, the company has recently obtained CE approval for its diagnostics kit in partnership with a company in the USA. Along with its diagnostics business, the company has a distribution business focusing on biological reagents and instruments.

About Curiox

Curiox Biosystems has a vision to accelerate the progress of life sciences and drug discovery through better miniaturization. Curiox is a bioinstrumentation company enabling the miniaturization of heterogeneous bioassay for researchers working in life sciences, drug discovery, and diagnostics. Curiox's patented miniaturization platform, DropArray™, provides up to 1,000 times savings in sample and reagent consumption, and up to 10 times reduction in assay time.

The company is located at Biopolis in Singapore, the biomedical hub of Singapore and Southeast Asia. The company is a spin-off from Institute of Bioengineering and Nanotechnology (IBN) backed primarily by Nanostart and Exploit Technologies, the commercializing arm of Singapore's Agency for Science, Technology and Research (A*STAR).

For further information, please visit www.curiox.com .

Media Contact:
Curiox Biosystems Pte Ltd
Public Relations
Dr. Namyong Kim
31 Biopolis Way #03-01
The Nanos
Singapore 138669

phone: +65 9151 3369
e-mail: namyong@curiox.com

กก